Alnylam to Webcast Conference Call Discussing Second Quarter 2026 Financial Results

Thu, 16 Jul 2026 08:00:00 -0400

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the second quarter ending June 30, 2026 on Thursday, July 30, 2026, before the U.S. financial markets open.

Management will provide an update on the Company and discuss second quarter 2026 results as well as expectations for the future via conference call on Thursday, July 30, 2026 at 8:30 am ET. A live audio webcast of the call will be available on the Investors section of the Company’s website at

Alnylam to Webcast Conference Call Discussing Second Quarter 2026 Financial Results

Thu, 16 Jul 2026 08:00:00 -0400

Alnylam to Webcast Conference Call Discussing Second Quarter 2026 Financial Results

Thu, 16 Jul 2026 08:00:00 -0400

Alnylam to Webcast Conference Call Discussing Second Quarter 2026 Financial Results

Thu, 16 Jul 2026 08:00:00 -0400

Alnylam advances Alzheimer's drug trials, reports mivelsiran safety data

Wed, 15 Jul 2026 05:50:14 -0400

Alnylam Pharmaceuticals (Nasdaq: ALNY) presented updates on its neuroscience pipeline at the Alzheimer's Association International Conference (AAIC) 2026, including new clinical trial initiations and updated safety data for its investigational drug mivelsiran.

The company initiated the APPlauDS Phase 2 study evaluating mivelsiran in people with Down syndrome-associated Alzheimer's disease (DS-AD). The trial will recruit participants with early-stage DS-AD across approximately 30 global sites. Michael S. Rafii, M.D., Ph.D., Professor of Neurology at the Keck School of Medicine of USC, described the study as "the first clinical trial to evaluate whether an RNAi approach can reduce APP overexpression caused by trisomy 21."

Alnylam

Alnylam advances Alzheimer's drug trials, reports mivelsiran safety data

Wed, 15 Jul 2026 05:50:14 -0400

Alnylam

Alnylam Highlights Progress with Neuroscience Programs at AAIC 2026, Showcasing Potential of RNAi in Neurological Disease

Wed, 15 Jul 2026 03:30:00 -0400

− Initiates Global Phase 2 APPlauDS Study of Mivelsiran in Down Syndrome–Associated Alzheimer’s Disease (DS-AD) −

− Announces Completion of Enrollment in the Phase 2 cAPPricorn-1 Study of Mivelsiran in Cerebral Amyloid Angiopathy (CAA) −

− Presents Updated Phase 1 Data on Mivelsiran in Early Onset Alzheimer’s Disease (EOAD) Showing Low Incidence of Amyloid-Related Imaging Abnormalities (ARIA) −

− Shares Preclinical Data and Design of Ongoing Phase 1 Study of Tau-Targeting ALN‑5288 in Alzheimer’s Patients –

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today shared advances across

Alnylam Highlights Progress with Neuroscience Programs at AAIC 2026, Showcasing Potential of RNAi in Neurological Disease

Wed, 15 Jul 2026 03:30:00 -0400

− Initiates Global Phase 2 APPlauDS Study of Mivelsiran in Down Syndrome–Associated Alzheimer’s Disease (DS-AD) −

− Announces Completion of Enrollment in the Phase 2 cAPPricorn-1 Study of Mivelsiran in Cerebral Amyloid Angiopathy (CAA) −

− Presents Updated Phase 1 Data on Mivelsiran in Early Onset Alzheimer’s Disease (EOAD) Showing Low Incidence of Amyloid-Related Imaging Abnormalities (ARIA) −

− Shares Preclinical Data and Design of Ongoing Phase 1 Study of Tau-Targeting ALN‑5288 in Alzheimer’s Patients –

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today shared advances across

Alnylam Highlights Progress with Neuroscience Programs at AAIC 2026, Showcasing Potential of RNAi in Neurological Disease

Wed, 15 Jul 2026 03:30:00 -0400

− Initiates Global Phase 2 APPlauDS Study of Mivelsiran in Down Syndrome–Associated Alzheimer’s Disease (DS-AD) −

− Announces Completion of Enrollment in the Phase 2 cAPPricorn-1 Study of Mivelsiran in Cerebral Amyloid Angiopathy (CAA) −

− Presents Updated Phase 1 Data on Mivelsiran in Early Onset Alzheimer’s Disease (EOAD) Showing Low Incidence of Amyloid-Related Imaging Abnormalities (ARIA) −

− Shares Preclinical Data and Design of Ongoing Phase 1 Study of Tau-Targeting ALN‑5288 in Alzheimer’s Patients –

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today shared advances across

Alnylam Highlights Progress with Neuroscience Programs at AAIC 2026, Showcasing Potential of RNAi in Neurological Disease

Wed, 15 Jul 2026 03:30:00 -0400

− Initiates Global Phase 2 APPlauDS Study of Mivelsiran in Down Syndrome–Associated Alzheimer’s Disease (DS-AD) −

− Announces Completion of Enrollment in the Phase 2 cAPPricorn-1 Study of Mivelsiran in Cerebral Amyloid Angiopathy (CAA) −

− Presents Updated Phase 1 Data on Mivelsiran in Early Onset Alzheimer’s Disease (EOAD) Showing Low Incidence of Amyloid-Related Imaging Abnormalities (ARIA) −

− Shares Preclinical Data and Design of Ongoing Phase 1 Study of Tau-Targeting ALN‑5288 in Alzheimer’s Patients –

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today shared advances across

Alnylam Pharmaceuticals (ALNY) Reiterated at Buy by Stifel Post CARDIO-TTRansform Failure

Tue, 14 Jul 2026 07:29:47 -0400

Stifel analyst Paul Matteis reiterated a Buy rating and $444.00 price target on Alnylam Pharmaceuticals (NASDAQ: ALNY).

The analyst commented, "ALNY shares traded sharply higher on the CARDIOTTRansform failure, but then retraced gains as many investors have concluded that the benefits of removing a competing silencer from the TTR-CM market are counterbalanced by greater implied risk to the nucresiran CVOT; in other words, ALNY gets back ~30% market share that could've gone to eplontersen, but now is at risk of never eradicating the 20%-30% royalty owed to SNY on vutrisiran. The debate here rests on the complete lack of benefit for

Alnylam Pharmaceuticals (ALNY) PT Raised to $485 at H.C. Wainwright

Tue, 14 Jul 2026 06:55:27 -0400

(Updated - July 14, 2026 6:55 AM EDT)

H.C. Wainwright analyst Patrick Trucchio raised the price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) to $485.00 (from $470.00) while maintaining a Buy rating.

The analyst commented: "On July 9, AstraZeneca and Ionis Pharmaceuticals announced that the Phase 3 CARDIO-TTRansform trial (n=1,432) evaluating eplontersen, an antisense oligonucleotide (ASO) in ATTR-CM, missed its primary endpoint, a composite of cardiovascular (CV) mortality and recurrent CV clinical events through Week 140. We view the CARDIO-TTRansform failure as idiosyncratic to eplontersen rather than a read-through to the silencer mechanism, leaving Alnylam's AMVUTTRA (vutrisiran) as the only ATTR therapy labeled

Alnylam Pharmaceuticals (ALNY) PT Raised to $485 at H.C. Wainwright

Tue, 14 Jul 2026 06:55:27 -0400

(Updated - July 14, 2026 6:55 AM EDT)

H.C. Wainwright analyst Patrick Trucchio raised the price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) to $485.00 (from $470.00) while maintaining a Buy rating.

Alnylam Pharmaceuticals (ALNY) PT Raised to $485 at H.C. Wainwright

Tue, 14 Jul 2026 06:55:27 -0400

(Updated - July 14, 2026 6:55 AM EDT)

H.C. Wainwright analyst Patrick Trucchio raised the price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) to $485.00 (from $470.00) while maintaining a Buy rating.

Alnylam Pharmaceuticals (ALNY) PT Lowered to $410 at BofA Securities

Tue, 14 Jul 2026 06:02:37 -0400

BofA Securities analyst Tazeen Ahmad lowered the price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) to $410.00 (from $460.00) while maintaining a Buy rating.

The analyst comments "For 2Q revenues, we model Amvuttra: $1,095mn (+23% q/q, cons: $1,048mn), Onpattro: $24.6mn (+20% q/q, cons: $24.6mn), Givlaari: $87mn (+17% q/q, cons: $85mn) and Oxlumo: $55mn (+7% q/q, cons: $54mn). We highlight 1Q was impacted by insurance reauthorizations, fewer shipping weeks and lower ex-US revenues, but these headwinds normalized in 2Q. ALNY reiterated the $4.4-4.7bn TTR guidance, and we think 2Q will be particularly important to inform where in the guidance range 2026 revenues will

Alnylam Pharmaceuticals (ALNY) PT Lowered to $410 at BofA Securities

Tue, 14 Jul 2026 06:02:37 -0400

BofA Securities analyst Tazeen Ahmad lowered the price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) to $410.00 (from $460.00) while maintaining a Buy rating.

Alnylam Pharmaceuticals (ALNY) PT Lowered to $410 at Truist Securities

Mon, 13 Jul 2026 07:40:34 -0400

(Updated - July 13, 2026 7:40 AM EDT)

Truist Securities analyst Danielle Brill lowered the price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) to $410.00 (from $505.00) while maintaining a Buy rating.

The analyst commented: "ALNY (Buy; PT lowered to $410 from $505). We expect Amvuttra to deliver an inline to modestly better-than-expected 2Q, with prescription trends and June demand (+17% month/ month) suggesting sales should land at or slightly above consensus. However, while near-term execution remains solid, we believe the long-term growth outlook for the ATTR franchise has become meaningfully more uncertain following the failure

Alnylam Pharmaceuticals (ALNY) PT Lowered to $410 at Truist Securities

Mon, 13 Jul 2026 07:40:34 -0400

(Updated - July 13, 2026 7:40 AM EDT)

Truist Securities analyst Danielle Brill lowered the price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) to $410.00 (from $505.00) while maintaining a Buy rating.

Alnylam Pharmaceuticals (ALNY) PT Raised to $400 at Morgan Stanley

Fri, 10 Jul 2026 08:09:08 -0400

Morgan Stanley analyst Andrew Galler raised the price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) to $400.00 (from $370.00) while maintaining a Equalweight rating.

Increasing unusual call volume: ACI LEVI IHI FE KHC BBIO IONS OCUL XME DOMO ALNY

Thu, 09 Jul 2026 10:33:50 -0400

Increasing unusual call volume: ACI LEVI IHI FE KHC BBIO IONS OCUL XME DOMO ALNY

Stifel: 'We expect IONS shares to trade lower today and ALNY shares to be volatile'

Thu, 09 Jul 2026 06:16:31 -0400

Stifel: 'We expect IONS shares to trade lower today and ALNY shares to be volatile'.

The analyst comments "We expect IONS (Hold, $84.46) shares to trade lower today, and ALNY (Buy, $323.50) shares to be volatile, on the surprising result that the CARDIO-TTRansform study for eplontersen in TTR-CM failed to meet its primary outcome. The study here was expected to work since we know TTR silencers are effective--the question going in was whether eplontersen can match the effect sizes seen for ALNY's vutrisiran, given that CARDIO-TTRansform was (1) a slightly shorter duration in (2) a possibly different/slightly milder population with (3)

Stifel: 'We expect IONS shares to trade lower today and ALNY shares to be volatile'

Thu, 09 Jul 2026 06:16:31 -0400

Stifel: 'We expect IONS shares to trade lower today and ALNY shares to be volatile'.

Stifel: 'We expect IONS shares to trade lower today and ALNY shares to be volatile'

Thu, 09 Jul 2026 06:16:31 -0400

Stifel: 'We expect IONS shares to trade lower today and ALNY shares to be volatile'.

Stifel: 'We expect IONS shares to trade lower today and ALNY shares to be volatile'

Thu, 09 Jul 2026 06:16:31 -0400

Stifel: 'We expect IONS shares to trade lower today and ALNY shares to be volatile'.

Canaccord Reiterates Buy Rating on Alnylam Pharmaceuticals (ALNY)

Tue, 30 Jun 2026 06:51:07 -0400

Canaccord analyst Whitney Ijem reiterated a Buy rating and $429.00 price target on Alnylam Pharmaceuticals (NASDAQ: ALNY).

The analyst commented: "Last week ALNY held its first “RNAi Roundtable” of 2026 (10th series), starting with ALN-6400: Targeting Plasminogen to Address a Wide Range of Bleeding Disorders. In addition to a review of Phase 1 data, Phase 2 study design and status, and next steps, we also heard from KOLs and a patient to underscore the unmet need in both hereditary hemorrhagic telangiectasia (HHT) and Von Willebrand Disease (VBD). Looking ahead, we’re focused on the top line Phase 2 data in HHT as

StreetInsider.com News Articles

Alnylam to Webcast Conference Call Discussing Second Quarter 2026 Financial Results

Alnylam to Webcast Conference Call Discussing Second Quarter 2026 Financial Results

Alnylam to Webcast Conference Call Discussing Second Quarter 2026 Financial Results

Alnylam to Webcast Conference Call Discussing Second Quarter 2026 Financial Results

Alnylam advances Alzheimer's drug trials, reports mivelsiran safety data

Alnylam advances Alzheimer's drug trials, reports mivelsiran safety data

Alnylam Highlights Progress with Neuroscience Programs at AAIC 2026, Showcasing Potential of RNAi in Neurological Disease

Alnylam Highlights Progress with Neuroscience Programs at AAIC 2026, Showcasing Potential of RNAi in Neurological Disease

Alnylam Highlights Progress with Neuroscience Programs at AAIC 2026, Showcasing Potential of RNAi in Neurological Disease

Alnylam Highlights Progress with Neuroscience Programs at AAIC 2026, Showcasing Potential of RNAi in Neurological Disease

Alnylam Pharmaceuticals (ALNY) Reiterated at Buy by Stifel Post CARDIO-TTRansform Failure

Alnylam Pharmaceuticals (ALNY) PT Raised to $485 at H.C. Wainwright

Alnylam Pharmaceuticals (ALNY) PT Raised to $485 at H.C. Wainwright

Alnylam Pharmaceuticals (ALNY) PT Raised to $485 at H.C. Wainwright

Alnylam Pharmaceuticals (ALNY) PT Lowered to $410 at BofA Securities

Alnylam Pharmaceuticals (ALNY) PT Lowered to $410 at BofA Securities

Alnylam Pharmaceuticals (ALNY) PT Lowered to $410 at Truist Securities

Alnylam Pharmaceuticals (ALNY) PT Lowered to $410 at Truist Securities

Alnylam Pharmaceuticals (ALNY) PT Raised to $400 at Morgan Stanley

Increasing unusual call volume: ACI LEVI IHI FE KHC BBIO IONS OCUL XME DOMO ALNY

Stifel: 'We expect IONS shares to trade lower today and ALNY shares to be volatile'

Stifel: 'We expect IONS shares to trade lower today and ALNY shares to be volatile'

Stifel: 'We expect IONS shares to trade lower today and ALNY shares to be volatile'

Stifel: 'We expect IONS shares to trade lower today and ALNY shares to be volatile'

Canaccord Reiterates Buy Rating on Alnylam Pharmaceuticals (ALNY)